SCI Cancer Clinical Trials Office Blog

News & Updates from the SCI-CCTO
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
  • Cancer Clinical Trials Office
  • Stanford Cancer Institute

Changes to SAE Entry in OnCore

December 9, 2020 - Katy McCormack

Consistent with the new SCI Data Safety and Monitoring Plan, Serious adverse event (SAE) entry into OnCore is changing for investigator-initiated studies (IIS/IIT).  There are 2 major changes. 

  • The DSMC will review all SAEs (new and follow‑ups), instead of the previous criteria of SAEs Grade 3 and higher.  All SAEs regardless of grade should be emailed (SECURE) to CCTO-Safety@stanford.edu.
  • PI signature on the SAE form is required for OnCore submission.  CCTO-Regulatory will hold on entry of SAEs that do not have the PI signature, as the group cannot take action on medical information unless it is documented as the determination of the investigator.  Secure digital signature on the PDF form is acceptable for submission to CCTO-Safety / CCTO-Regulatory. 

SAE reports should be submitted to CCTO-Safety promptly, although there is no explicit due date. It is recommended that reports to CCTO-Safety should occur concurrent with the first notification to any other party of interest (industry collaborator, IRB, FDA, etc), which have explicit timeframes for reporting some or all SAEs.

Please ensure that all SAEs submitted to CCTO-Safety have been reviewed and signed by the investigator.

Blog Submissions

If you have an announcement for the blog, please complete the Comms Request Form.

Reminder: Please have your blog post submitted to us by noon on Wednesday in order to have your post featured in the weekly email digest on Friday morning.

Archives

Categories

  • Announcements
  • Clinical Trials
  • Coordinator Corner
  • Educational Training
  • Events
  • Intake Process
  • IRB Updates
  • kudos
  • OnCore
  • PRISM
  • Quality Corner
  • Regulatory Updates
  • Remote Monitoring
  • SCI Messages
  • Scientific Review Committee (SRC)
  • SOP/Guideline Updates
  • Staff Updates
  • Uncategorized
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube